KalVista Pharmaceuticals (id:6660 KALV)
10.15 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:36:26 PM)
Exchange closed, opens in 1 day 10 hours
About KalVista Pharmaceuticals
Market Capitalization 499.54M
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
| Headquarters (address) |
55 Cambridge Parkway Cambridge 02142 MA United States |
| Phone | 857 999 0075 |
| Website | https://www.kalvista.com |
| Employees | 150 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | KALV |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 7.39 - 16.88 |
| Market Capitalization | 499.54M |
| P/E trailing | -2.95 |
| P/E forward | -5.43 |
| Price/Book | 2.53 |
| Beta | 0.913 |
| EPS | -3.57 |
| EPS United States (ID:6, base:3403) | 24.22 |